Croissy-Beaubourg and Montpellier, may 11, 2017 18: 15 CEST THERADIAG (ISIN : FR0004197747, Ticker : ALTER, eligible PEA-PME), a company specialized in the in vitro diagnostic and theranostic, today announced the launch of a capital increase by issuing new shares with cancellation of preferential subscription rights to the benefit of a category of beneficiaries, pursuant to the 15th resolution approved by the combined General Meeting of shareholders of 27 April 2017 and authorization of the Board of directors of may 11, 2017 (the ” Transaction “). The amount of the Transaction will be a maximum of 4 million euros. The new shares will be the subject of an application for admission on Alternext Paris to Euronext Paris.
Download the free guide
Boost your gains
The next class of beneficiaries for whose benefit the preferential subscription right is waived, the funds will only be raised from qualified investors, domestic and international, with the exception of the United States, Canada, Australia and Japan. They will allow Theradiag to facilitate and accelerate its international development and, in particular, the launch of the BioCLIA® in Europe as well as the marketing of the ranges of auto-immunity, allergy and theranostic.
The Operation may be carried out by accelerated building of an order book at the end of which will be determined the number and price of the new shares issued. The accelerated construction of the book of orders will begin immediately and is expected to close before the opening of trading on Friday 12 may, subject to any early closing or extension. The Company will announce the result of the Operation as soon as possible after the closing of the order book in a press release. Under the 15th resolution of the combined General Meeting of shareholders of 27 April 2017, the issue price of the new shares will be at least equal to the average weighted by the volumes of the last five stock market sessions preceding the fixing of the issue price, minus a maximum discount of 20%.
The new shares will bear dividend rights common and will be admitted to trading on the Alternext Paris under ISIN code FR0004197747, ALTER.
The Company also announces that it has been informed by its main shareholder, Truffle Capital, acting on behalf of the investment fund of which it is the management company, the crossing downwards of the thresholds of 10% and 5% of the share capital and voting rights. Truffle Capital has clarified that the relevant funds have more than 1,04% of the capital of the company prior to completion of the capital increase.
EuroLand Corporate has stepped in as council in the framework of the Operation.
In accordance with the provisions of article 211-3 of the general Regulation of the Autorité des marchés financiers, the offer of shares of the Company within the framework of this capital increase made for the benefit of a class of beneficiaries, will not give rise to a prospectus submitted to the visa of the Autorité des marchés financiers. Detailed information about the Company, including relating to its business, its results and the risk factors corresponding, are included in the annual financial report for the fiscal year ended December 31, 2016, which may be consulted, as well as other regulated information and all press releases of the Company, on its website (www.theradiag.com).
Download the free guide
Boost your gains
